Shitij Kapur, MD, PhD, FRCPC

Article

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

October 26, 2016

When your patients with schizophrenia insufficiently respond to antipsychotic treatment, do you increase the dose? Do you check their plasma drug concentration? Read this CME article to find out...

Hitoshi Sakurai, Takefumi Suzuki, Robert R. Bies, et al

Original Research

Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials

April 15, 2014

Jonathan Rabinowitz, Nomi Werbeloff, Ivo Caers, et al

Original Research

An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis

March 8, 2011

Ofer Agid, Tamara Arenovich, Gautam Sajeev, et al

Original Research

Relationship Between Daily Dose, Plasma Concentrations, Dopamine Receptor Occupancy, and Clinical Response to Quetiapine: A Review

January 25, 2011

Anna Sparshatt, David Taylor, Maxine X. Patel, et al

Original Research

"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial

September 7, 2010

Gary Remington, Philip Seeman, Alan Feingold, et al

Original Research

A Systematic Review of Aripiprazole—Dose, Plasma Concentration, Receptor Occupancy, and Response: Implications for Therapeutic Drug Monitoring

June 1, 2010

Anna Sparshatt, David Taylor, Maxine X. Patel, et al

Original Research

Increased Antipsychotic Sensitivity in Elderly Patients: Evidence and Mechanisms

December 16, 2009

Hiroyuki Uchida, David C. Mamo, Benoit H. Mulsant, et al

Original Research

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

August 31, 2008

Hiroyuki Uchida, David C. Mamo, Shitij Kapur, et al

Original Research

Quetiapine Extended-Release Versus Immediate-Release Formulation: A Positron Emission Tomography Study

January 15, 2008

David C. Mamo, Hiroyuki Uchida, Irina Vitcu, et al

Original Research

Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade

November 1, 2002

Sitra Tauscher-Wisniewski, Shitij Kapur, Johannes Tauscher, et al

Letter to the Editor

Reply to Letter to the Editor "Need for a New Framework to Understand the Mechanism of All Antipsychotics"

October 31, 2000

Gary J. Remington, Shitij Kapur

Article

D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET

October 1, 1999

Gary Remington, Shitij Kapur

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials

An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis

Relationship Between Daily Dose, Plasma Concentrations, Dopamine Receptor Occupancy, and Clinical Response to Quetiapine: A Review

"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial

A Systematic Review of Aripiprazole—Dose, Plasma Concentration, Receptor Occupancy, and Response: Implications for Therapeutic Drug Monitoring

Increased Antipsychotic Sensitivity in Elderly Patients: Evidence and Mechanisms

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

Quetiapine Extended-Release Versus Immediate-Release Formulation: A Positron Emission Tomography Study

Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade

Reply to Letter to the Editor "Need for a New Framework to Understand the Mechanism of All Antipsychotics"

D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET

ELSEWHERE:

FOLLOW US:

Shitij Kapur, MD, PhD, FRCPC

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials

An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis

Relationship Between Daily Dose, Plasma Concentrations, Dopamine Receptor Occupancy, and Clinical Response to Quetiapine: A Review

"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial

A Systematic Review of Aripiprazole—Dose, Plasma Concentration, Receptor Occupancy, and Response: Implications for Therapeutic Drug Monitoring

Increased Antipsychotic Sensitivity in Elderly Patients: Evidence and Mechanisms

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

Quetiapine Extended-Release Versus Immediate-Release Formulation: A Positron Emission Tomography Study

Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade

Reply to Letter to the Editor "Need for a New Framework to Understand the Mechanism of All Antipsychotics"

D2 and 5-HT2 Receptor Effects of Antipsychotics: Bridging Basic and Clinical Findings Using PET

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles